Calcineurin inhibitors in the treatment of systemic lupus erythematosus during pregnancy : A narrative review with emphasis on efficacy and safety
Copyright © 2024 Elsevier B.V. All rights reserved..
Systemic lupus erythematosus (SLE) predominantly affects child-bearing women, leading to an elevated risk of maternal and fetal complications and adverse pregnancy outcomes. Since some medications can cross the placental barrier that persist a threat to both mother and fetus, the risk-benefit ratio of SLE medications should be taken into consideration during pregnancy. Calcineurin inhibitor (CNI), mainly including cyclosporin A, tacrolimus, and voclosporin, is a category of immunosuppressive agents that inhibit calcium/calmodulin-dependent phosphatase calcineurin to block T cell activation. Based on the current clinical evidence, CNI is an alternative in pregnant SLE patients with persistent disease activity (especially lupus nephritis patients) and non-responders to azathioprine. However, there is no comprehensive review that summarizes the efficacy and safety profile of CNI for SLE management during pregnancy. This review presents a summary on the utilization of CNI for SLE management during pregnancy, including the mechanism of action, gestational amelioration of lupus flare, and the balance of maternal benefit-fetal risk, which may provide more references for the management of SLE pregnancies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:294 |
|---|---|
| Enthalten in: |
European journal of obstetrics, gynecology, and reproductive biology - 294(2024) vom: 20. Feb., Seite 148-155 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jiang, Yi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Calcineurin Inhibitors |
|---|
| Anmerkungen: |
Date Completed 21.02.2024 Date Revised 21.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejogrb.2023.12.039 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367364492 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367364492 | ||
| 003 | DE-627 | ||
| 005 | 20240222091707.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240122s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejogrb.2023.12.039 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1301.xml |
| 035 | |a (DE-627)NLM367364492 | ||
| 035 | |a (NLM)38245953 | ||
| 035 | |a (PII)S0301-2115(23)00889-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jiang, Yi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Calcineurin inhibitors in the treatment of systemic lupus erythematosus during pregnancy |b A narrative review with emphasis on efficacy and safety |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.02.2024 | ||
| 500 | |a Date Revised 21.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier B.V. All rights reserved. | ||
| 520 | |a Systemic lupus erythematosus (SLE) predominantly affects child-bearing women, leading to an elevated risk of maternal and fetal complications and adverse pregnancy outcomes. Since some medications can cross the placental barrier that persist a threat to both mother and fetus, the risk-benefit ratio of SLE medications should be taken into consideration during pregnancy. Calcineurin inhibitor (CNI), mainly including cyclosporin A, tacrolimus, and voclosporin, is a category of immunosuppressive agents that inhibit calcium/calmodulin-dependent phosphatase calcineurin to block T cell activation. Based on the current clinical evidence, CNI is an alternative in pregnant SLE patients with persistent disease activity (especially lupus nephritis patients) and non-responders to azathioprine. However, there is no comprehensive review that summarizes the efficacy and safety profile of CNI for SLE management during pregnancy. This review presents a summary on the utilization of CNI for SLE management during pregnancy, including the mechanism of action, gestational amelioration of lupus flare, and the balance of maternal benefit-fetal risk, which may provide more references for the management of SLE pregnancies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Calcineurin inhibitor | |
| 650 | 4 | |a Efficacy | |
| 650 | 4 | |a Pregnancy | |
| 650 | 4 | |a Safety | |
| 650 | 4 | |a Systemic lupus erythematosus | |
| 650 | 7 | |a Calcineurin Inhibitors |2 NLM | |
| 700 | 1 | |a Tao, Min |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Jingjing |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Lihua |e verfasserin |4 aut | |
| 700 | 1 | |a You, Qingxia |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Nian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of obstetrics, gynecology, and reproductive biology |d 1974 |g 294(2024) vom: 20. Feb., Seite 148-155 |w (DE-627)NLM000469130 |x 1872-7654 |7 nnns |
| 773 | 1 | 8 | |g volume:294 |g year:2024 |g day:20 |g month:02 |g pages:148-155 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejogrb.2023.12.039 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 294 |j 2024 |b 20 |c 02 |h 148-155 | ||